MetasTx LLC

MetasTx is creating treatments that prevent and treat prostate cancer metastasis without affecting the Androgen System. An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%. This area of research is ripe for advances. Unfortunately, current drug discovery in metastatic cancer has not resulted in therapies with significant increases in patient survival, specificity in drug delivery, or mitigation of deleterious side effects. MetasTx drug development program is focused on novel molecules that were designed and synthesized in the laboratory of Dr. David Crich, PhD. Patent applications have been filed by the University of Georgia Research Foundation from whom MetasTx plans to license the IP for these molecules. The two best compounds are being tested and analyzed through a cascade of biochemical and cellular assays for efficacy and safety, under the direction of MetasTx, with plans in place for studies that will support a New Drug Application and likely progression to the First-In-Human (Phase 1/2a) clinical study by late 2027/early 2028. Generative AI will be employed to discover improved next generation compounds. Concurrently, work is progressing to identify the relevant signature biomarkers, and the development of methods for their early detection for diagnostic purposes. This proof of principle project for EMT Signature Markers, has been awarded funding from the National Cancer Institute and is expected to be completed by Q2 2026. This will lead to development of a Companion Diagnostic that will be used to identify patients with PCa who are likely to need aggressive treatment to prevent metastasis. This will streamline enrollment into clinical trials, which will reduce costs and significantly speed up bringing our new drugs to FDA for approval.